With more than 795,000 cases occurring every year, stroke has become a major problem in
the United States across all demographics. Stroke is the leading cause of long-term …

The blood–brain barrier (BBB) is formed primarily to protect the brain microenvironment from
the influx of plasma components, which may disturb neuronal functions. The BBB is a …

Intravascular administration of plasminogen activators is a clinically important thrombolytic
strategy to treat occlusive vascular conditions. A major issue with this strategy is the systemic …

Blood–brain barrier (BBB) disruption, mediated through matrix metalloproteinases (MMPs)
and other mechanisms, is a critical event during ischemic stroke. Tissue plasminogen …

Today there exists only one FDA-approved treatment for ischemic stroke; ie, the serine
protease tissue-type plasminogen activator (tPA). In the aftermath of the failed stroke clinical …

In recent years, there has been a considerable increase in interest in the use of transgenic
plants as sources of valuable secondary metabolites or recombinant proteins. This has been …

Stroke disrupts the homeostatic balance within the brain and is associated with a significant
accumulation of necrotic cellular debris, fluid, and peripheral immune cells in the central …

Neuroplasticity is a natural process occurring in the brain for the entire life. Stroke is the
leading cause of long term disability and a huge medical and financial problem throughout …

Tissue Plasminogen Activator - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog …

Acting as a double-edged sword, the blood–brain barrier (BBB) is essential for maintaining
brain homeostasis by restricting the entry of small molecules and most macromolecules from …